TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma
NCT ID: NCT04559607
Last Updated: 2023-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
188 participants
INTERVENTIONAL
2020-09-11
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental group: TACE+Camrelizumab+Apatinib
Camrelizumab (iv. infusion of 200 mg); Apatinib (po. administration of 250 mg); TACE
Camrelizumab
Camrelizumab: 200mg, iv, Q3W
TACE
TACE if necessary
Apatinib
Apatinib: 250m, po, QD
Control group: TACE
TACE
TACE
TACE if necessary
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Camrelizumab
Camrelizumab: 200mg, iv, Q3W
TACE
TACE if necessary
Apatinib
Apatinib: 250m, po, QD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
-≥18 years
* China liver cancer staging: Ib-IIIa
* Child-Pugh score ≤6 point
* Previous TACE treatment(≤2 times) is permitted
* Adequate organ and marrow function
Exclusion Criteria
* Participants who have severe allergy to iodine, and unable to receive TACE
* Participants who have undergone a liver transplant or allogeneic bone marrow transplantation, or those who are in the waiting list for liver or bone marrow transplantation
* Participants who had congenital or acquired immune deficiency, such as HIV infection
* Participants who had a history of gastrointestinal bleeding within 6 months prior to randomization or a definite tendency of gastrointestinal bleeding
* Participants who had undergone arterial thromboembolism within 6 months prior to randomization or a definite tendency of gastrointestinal bleeding, such as cerebrovascular accident, ≥ CTCAE grade 3 deep vein thrombosis and pulmonary embolism
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhongda Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gao-jun Teng
Chief physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gao-Jun Teng, Doctor
Role: PRINCIPAL_INVESTIGATOR
Zhongda Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongda Hospital
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MA-HCC-II-005
Identifier Type: -
Identifier Source: org_study_id